Latham & Watkins advised Arcutis Biotherapeutics, Inc. in the offering, while Cooley represented the underwriters.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the pricing of its underwritten public…
Arcutis Biotherapeutics’ $150 Million Shares Offering
